of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: March 25, 2005.

#### William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 05–6585 Filed 4–1–05; 8:45 am] BILLING CODE 4410–09–P

# DEPARTMENT OF JUSTICE

### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Registration

By Notice dated December 21, 2004, and published in the **Federal Register** on January 4, 2005, (70 FR 390), Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule II:

| Drug  | Schedule |
|---|----------|
| Dihydrocodeine (9120)<br>Remifentanil (9739)<br>Sufentanil (9740) |          |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33(a), the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: March 25, 2005. **William J. Walker,** Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–6592 Filed 4–1–05; 8:45 am] **BILLING CODE 4410–09–P** 

## DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

# Manufacturer of Controlled Substances; Notice of Application

Pursuant to 21 CFR 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 7, 2005, Johnson Matthey, Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of Methamphetamine (1105), a basic class of controlled substance listed in Schedule II.

The company plans to manufacture the listed controlled substance in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than June 3, 2005.

Dated: March 25, 2005.

### William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 05–6586 Filed 4–1–05; 8:45 am] BILLING CODE 4410-09–P

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations

(CFR), this is notice that on January 4, 2005, Mallinckrodt Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:

| Drug   | Schedule |
|--|----------|
| Tetrahydrocannabinols (7370)                 | 1        |
| Codeine-N-oxide (9053)                       | 1        |
| Dihydromorphine (9145)                       |          |
| Difenoxin (9168)                             |          |
| Heroin (9200)                                |          |
| Morphine-N-oxide (9307)                      |          |
| Nicomorphine (9312)                          |          |
| Normorphine (9312)                           |          |
| Norlevorphanol (9634)                        |          |
|  |          |
| Amphetamine (1100)<br>Methamphetamine (1105) |          |
|  |          |
| Methylophenidate (1724)                      |          |
| Codeine (9050)<br>Diprenorphine (9058)       |          |
| Diprenorphine (9058)                         |          |
| Etorphine HCL (9059)                         |          |
| Dihydrocodeine (9120)                        |          |
| Hydromorphone (9150)                         |          |
| Oxycodone (9143)                             |          |
| Diphenoxylate (9170)                         |          |
| Benzoylecgonine (9180)                       |          |
| Hydrocodone (9193)                           |          |
| Levorphanol (9220)                           | 11       |
| Meperidine (9230)                            | 11       |
| Methadone (9250)                             | 11       |
| Methadone Intermediate (9254)                |          |
| Metopon (9260)                               | 11       |
| Dextropropoxyphene (9273)                    | II       |
| Morphine (9300)                              | 11       |
| Thebaine (9333)                              | II       |
| Opium extracts (9610)                        | II       |
| Opium fluid extract (9620)                   | П        |
| Opium tincture (9630)                        | II       |
| Opium, powdered (9639)                       | Ш        |
| Opium, granulated (9640)                     | Ш        |
| Levo-alphacetylmethadol (9648)               | П        |
| Oxymorphone (9652)                           | II       |
| Alfentanil (9737)                            | II       |
| Remifentanil (9739)                          | II       |
| Sufentanil (9740)                            | II       |
| Fentanyl (9801)                              | II       |
| · · ·  |          |

The company plans to manufacture the listed controlled substances for internal use and for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to